Šalis: Airija
kalba: anglų
Šaltinis: HPRA (Health Products Regulatory Authority)
Neomycin ; Penethamate; Benzylpenicillin
Cross Vetpharm Group Limited
QJ51RC
Neomycin ; Penethamate; Benzylpenicillin
70000 IU, 77.2 mg, 227.2 mg per syringe
Intramammary suspension
POM: Prescription Only Medicine as defined in relevant national legislation
Cattle
Beta-lactam antibacterials, penicillins, combinations with other antibacterials
Antibacterial
Authorised
2013-01-25
Health Products Regulatory Authority 11 January 2018 CRN000VGY Page 1 of 6 1 NAME OF THE VETERINARY MEDICINAL PRODUCT Multishield DC Intramammary Suspension for Cows 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each 4.5g intramammary syringe contains Active Substances: Neomycin 70 000 IU (corresponding to Neomycin Sulphate 100 mg) Penethamate 77.2 mg (corresponding to Penethamate Hydriodide 100 mg) Benzylpenicillin 227.2 mg (corresponding to Procaine Benzylpenicillin 400 mg) Excipients: For a full list of excipients, see section 6.1. 3 PHARMACEUTICAL FORM Intramammary suspension. A smooth, off white, oily suspension. 4 CLINICAL PARTICULARS 4.1 TARGET SPECIES Cows (at dry off) 4.2 INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES In cows at drying off: Treatment of subclinical mastitis caused by bovine mastitis microorganisms susceptible to the combination of active substances, penicillin and neomycin, and as part of strategy for the prevention of new infections occurring during the dry period. 4.3 CONTRAINDICATIONS Do not use in lactating cows. Do not use in cases of hypersensitivity to β-lactam antibiotics, cephalosporin antibiotics, neomycin or other aminoglycoside antibiotics or to any of the excipients. Do not use in cows with clinical mastitis. Health Products Regulatory Authority 11 January 2018 CRN000VGY Page 2 of 6 4.4 SPECIAL WARNINGS FOR EACH TARGET SPECIES None. 4.5 SPECIAL PRECAUTIONS FOR USE SPECIAL PRECAUTIONS FOR USE IN ANIMALS Use of the product should be based on susceptibility testing of the bacteria isolated from the animal. If this is not possible, therapy should be based on local (regional, farm level) epidemiological information about susceptibility of the target bacteria. Official, national and regional antimicrobial policies should be taken into account when the product is used. The therapeutic efficacy of the product is only established against pathogens that are susceptible to the active substances. Serious acute mastitis [potentially lethal] due to pathogens like _Pseudomonas _ _aerugin Perskaitykite visą dokumentą